Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline
COYA•Partnership, cash and ownership details
Collaboration with Dr. Reddy’s includes up to about $700 million in milestones, mid-teen royalties, and a $10 million equity investment.
Cash totaled $43.2 million as of June 30, 2026; runway projected into H2 2027.
Shares outstanding were about 23,500,000 as of Aug. 11, 2026; Greenlight Capital held 9.9%, Dr. Reddy’s held 9.7%.
Investor presentation outlines neurodegeneration pipeline
Coya Therapeutics released an investor presentation outlining its Treg-directed combination-therapy strategy for neurodegenerative diseases.
Lead program COYA 302 targets ALS with Phase 2 ALSTARS enrollment expected to finish in H2 2026; topline data expected in Q1 2027.
